New Discovery: Cell State Makes Colon Cancer Resistant to Treatment"

Researchers from Mount Sinai, Max Delbrück Center and other international institutions have identified a novel cancer cell state that fuels resistance to therapy in colorectal cancer. The findings, which were published in “Nature Genetics,” reveal a new mechanism and potential drug target.

An international group of researchers in collaboration with Dr. Gaetano Gargiulo, Group Leader of the Molecular Oncology lab at the Max Delbrück Center, have uncovered a mechanism by which some colorectal cancers (CRC) resist treatment. Tumor cells can switch into a fetal-like state, they found, enabling them to evade chemotherapy and continue growing. The study was published in “Nature Genetics.”

A hidden escape mechanism

Colorectal cancer is the third most common cancer worldwide, according to the World Cancer Research Fund, and remains one of the deadliest malignancies. The five-year survival rate for CRC patients whose cancer has spread to distant sites in the body hovers around 15%, primarily because the cancer grows resistant to treatment.

In recent years, scientists have discovered that LGR5+ cancer stem cells fuel the progression of CRC. However, researchers have shown that destroying these cells alone does not lead to cancer remission. In this study, Dr. Slim Mzoughi and Dr. Ernesto Guccione and their colleagues at Mount Sinai’s Icahn School of Medicine identified another, previously unknown cell state that fuels CRC. The team named it Oncofetal (OnF) because it resembles fetal gut cells.

Genetic tracing yields clues

To confirm that these cells play an active role in tumor evolution and resistance to therapy, the Mount Sinai team partnered with Gargiulo and his team. In a mouse intestinal organoid model that mimics human CRC, the researchers used their proprietary synthetic genetic tracing technology to label and track OnF cells in real time. This provided direct evidence that these cells are not just passive bystanders, but key players in fueling tumor progression.

“We now know that rather than a single stem cell population, multiple cancer cell states coexist and cooperate, making tumors much harder to eliminate,” says Gargiulo. “With our versatile technology, we were well positioned to track a novel cell population and demonstrate their role in tumor evolution and therapy resistance. This study provides an unprecedented look at how tumors adapt to survive treatment and is a first step toward discovering new drugs that could dramatically improve patient outcomes and extend survival.”

Source: press release MDC ”New cell state drives colon cancer therapy resistance”, February 24, 2025

The future of medicine: Capital Region Innovation Center

The capital region has developed into a world-leading location for healthcare and life sciences thanks to close collaboration between leading global players, renowned scientists, first-class hospitals and an innovative start-up community. Interdisciplinary networks, highly specialized professionals, technology transfer and disruptive technologies play a crucial role in transforming scientific knowledge into innovative products for the global healthcare market.

For more information about the HealthCapital Berlin-Brandenburg cluster, the economic development of growth industries in the region, and business and technology funding for companies, investors and scientific institutions, please contact:

Melanie Gartzke I E-Mail